Sorting Cancers by ‘Immune Archetypes’ May Offer New Approach For Precision Immunotherapies
January 06, 2022
UCSF Researchers Uncover Common Immune Microenvironments Across Different Types of Cancer
MORE
QSant, the first urine test for kidney transplant rejection, Featured at Biotech Showcase Digital 2022
January 04, 2022
NephroSant, a biotechnology company launched on University of California, San Francisco technology, and dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, announced that it will present a company overview at the upcoming Biotech Showcase conference... See With Your Ears
December 22, 2021
Scott Harris, a UCSF Neuroscience PhD Candidate, Brings Home The Blackstone LanchPad Prize Global Blood Therapeutics granted FDA label expansion for sickle cell disease therapy
December 20, 2021
Global Blood Therapeutics is trading higher after the FDA expanded the approval for the company’s sickle cell disease therapy Oxbryta (voxelotor), allowing its use in children as young as four years of age. Oxbryta, discovered by Matthew Jacobson, chair of the Department of Pharmaceutical Chemistry... Neuvivo Launches to Develop Effective Treatments for ALS
December 09, 2021
Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases based on the University of California, San Francisco lab discoveries by co-founder Michael McGrath, today announced its corporate launch, the expansion of its executive team, and the creation... Exai Bio Launches Big in Series A Financing
December 09, 2021
Exai Bio, a next-generation liquid biopsy company based on the University of California, San Francisco’s technologies for early cancer detection developed in Dr. Neurona Therapeutics to Present New Data for Lead Neural Cell Therapy Program
December 07, 2021
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology. A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been... The Truth About Innovation
November 17, 2021
OTMA Executive Director Anthony Francis opens up about MedTech innovation and using the academic institution as a launchpad for startups.
MORE
Chroma Medicine Launches with $125M
November 17, 2021
Chroma Medicine, a NewCo based on UCSF technologies to advance programmable epigenetic editors that harness innate mechanisms to precisely control gene ex Neurona Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy in Epilepsy Patients
November 05, 2021
Neurona Therapeutics, a biotherapeutics company founded in UCSF technology to advance restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has received clearance of its Investigational New Drug (IND) application f